Business Context and Reporting Period
This Form 8-K was filed by Oncocyte Corporation (trading symbol: OCX) on February 23, 2023, reporting events occurring on February 16, 2023. The filing details the completion of a strategic asset disposition involving the sale of a majority stake in its wholly-owned subsidiary, Razor Genomics, Inc. ("Razor").
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of 70% of issued and outstanding equity interests in Razor Genomics, Inc. to Dragon Scientific, LLC.
- Shares Sold: 3,188,181 shares of Razor common stock.
- Monetary Consideration: The filing explicitly states that no monetary consideration was received for the sale of the 70% equity interest.
- Retained Interest: Oncocyte retains approximately 30% ownership (1,366,364 shares) in Razor following the closing.
- Assets Transferred: All assets and liabilities related to DetermaRx, a test for predicting cancer recurrence and chemotherapy response in early-stage lung cancer.
- Financial Impact: The transaction allows Oncocyte to eliminate all future development and commercialization costs associated with DetermaRx.
Material Changes Versus Prior Period
The primary material change is the divestiture of the DetermaRx business line. Prior to this date, Oncocyte bore 100% of the costs and risks associated with the development and commercialization of this asset. Post-closing, these obligations have been transferred to the new majority owner, Dragon Scientific, LLC, while Oncocyte maintains a minority stake.
Guidance, Outlook, and Management Commentary
Management commentary indicates a strategic shift to reduce cost burdens. The transaction was structured to offload development and commercialization expenses without immediate cash inflow. Additional agreements were executed to facilitate the transition:
- Transitional Consulting: Razor entered into agreements with two former Oncocyte employees in lieu of a formal transition services agreement.
- Records Custody: A Records Custody and Services Agreement was signed between Oncocyte, Razor, and the Buyer.
- Pro Forma Data: Unaudited pro forma consolidated financial information reflecting the closing is included as Exhibit 99.1.
Important Facts for Investor Verification
- Verify the valuation of the retained 30% stake in Razor Genomics, Inc., given that no cash was received for the 70% sold.
- Review Exhibit 99.1 (Unaudited Pro Forma Consolidated Financial Statements) to understand the immediate impact on Oncocyte's balance sheet and future expense recognition.
- Confirm the terms of the transitional consulting agreements to assess any ongoing financial obligations to the two former employees.
- Monitor the future performance of Razor Genomics to evaluate the potential value of Oncocyte's remaining minority interest.